Immucor and Sirona Genomics Announce CE Mark for MIA FORA™ NGS HLA Typing Solution

Immucor, Inc., a global leader in transfusion and transplantation diagnostics, in collaboration with Sirona Genomics, has announced CE Mark approval for its MIA FORA NGS offering for HLA typing.

“Since the launch of our MIA FORA NGS product last month, feedback from the HLA community has been overwhelmingly positive,” stated Michael Mindrinos, Ph.D., President and co-founder of Sirona. “With its manual and automated workflows, MIA FORA NGS is a versatile offering that can be used in HLA laboratories large or small. We are excited to be working with Immucor and HLA laboratories around the world to help bring the improved resolution from next generation sequencing to stem cell and solid organ typing.”

MIA FORA NGS is a high resolution HLA typing solution that enables accurate, comprehensive coverage and analysis of 11 HLA genes. The offering, which is adapted for use on the Illumina MiSeq® NGS platform, can be automated or run manually.

“European regulatory clearance is a significant milestone for MIA FORA NGS and is the result of strong teamwork between Immucor and Sirona Genomics,” stated Keith Chaitoff, Immucor’s Chief Marketing Officer. “We believe MIA FORA NGS is a differentiated product that is improving patient outcomes by helping to provide transplant recipients with better matched stem cells and solid organs. We are excited to now be able to offer this product to our customers requiring CE mark.”

Today’s announcement follows the worldwide launch of MIA FORA NGS in December 2015. A higher volume test kit for registry HLA typing is expected to launch this year. MIA FORA is available RUO in the U.S.